Carbapenem Resistance: Solutions for a Clear and Present Public Health Threat
Wednesday, November 6, 4 pm EST, Baltimore Convention Center
Patrice Allibert, PhD, MDx Consulting
Kathy Warye, CEO, Infection Prevention Partners
It is now well known that in 2050, infectious diseases will cause more deaths than cancer. One of the major reasons will be resistance to drugs. Organisms resistant to last-resort antibiotics such as Carbapenems represent a growing threat to public health across the globe.
In the US, the CDC has designated carbapenem-resistant Enterobacteriaceae (CRE) an urgent threat and referred to it as the “nightmare bacteria.” In the US alone, CRE has been estimated to cause 9,000 infections and 600 deaths per year (CDC). A 2014 study found that 41% of isolates were from patients who had asymptomatic colonization highlighting the importance of preemptive screening and timely intervention for prevention of transmission.1 The accurate detection of carbapenem-resistant organisms is a challenge for many clinical laboratories, key participants in the antimicrobial stewardship programs (ASP) that are being deployed to combat resistance. New molecular testing technologies will be a vital tool in the battle against resistance and promise to offer groundbreaking new opportunities to detect, prevent and manage MDROs.
1. Infect Control Hosp Epidemiol. 2014 Aug; 35(8): 978–983.